Tianma Microelectronics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

Tianma Microelectronics Co., Ltd. reported earnings for the nine months ending September 30, 2025, with sales of CNY 26,662.7 million, up from CNY 24,014.02 million the previous year. The company achieved a net income of CNY 313.12 million, recovering from a net loss of CNY 472.62 million a year ago. Basic and diluted earnings per share from continuing operations were CNY 0.1274, compared to losses of CNY 0.1923 in the prior year.

JI LIN AO DONG released its performance for the first three quarters, with a net profit attributable to the parent company of 2.26 billion yuan, a year-on-year increase of 81.70%

According to the Zhitong Finance APP, JI LIN AO DONG released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%. The net profit attributable to shareholders of the listed company was 2.26 billion yuan, a year-on-year increase of 81.70%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.99 billion yuan, a year-on-year increase of 65.20%

JI LIN AO DONG: The hydrochloride naloxone injection has passed the consistency evaluation of quality and efficacy for generic drugs

JI LIN AO DONG announced that its holding subsidiary Yanji Pharmaceutical has received the "Drug Supplement Application Approval Notice" for "Naloxone Hydrochloride Injection" issued by the National Medical Products Administration. The generic name of the drug is Naloxone Hydrochloride Injection, with a specification of 1ml: 0.4mg, and the original drug approval number is Guo Yao Zhun Zi H20066188. This approval through the consistency evaluation of the quality and efficacy of generic drugs is beneficial for expanding the market share of this drug and enhancing market competitiveness. It is expected that there will be no significant impact on the company's performance in the short term

The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit

JI LIN AO DONG's subsidiary has obtained the registration certificate for Shengxian Tang granules

According to the Zhitong Finance APP, JI LIN AO DONG announced that its holding subsidiary, JI LIN AO DONG TAONAN PHARMACEUTICAL CO., LTD. (referred to as "Taonan Pharmaceutical"), has received the "Drug Registration Certificate" for "Shengxian Decoction Granules" issued by the National Medical Products Administration. The function and indications of Shengxian Decoction Granules: tonifying qi and lifting the sinking. It is used for the syndrome of atmospheric sinking. Symptoms include shortness of breath, difficulty in breathing, weak and slow pulse, or disharmony of the pulse